Evaluating Metrics of Circulating Tumor DNA Response and Progression Using a High Sensitivity Tumor-Agnostic Assay in Metastatic HR+/HER2- Breast Cancer Receiving Endocrine Therapy and a CDK4/6-inhibitor.
Journal of Clinical Oncology(2024)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要